Guggenheim initiated coverage on Tourmaline with a new price target
$TRML
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Guggenheim initiated coverage of Tourmaline with a rating of Buy and set a new price target of $50.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/23/2025 | $70.00 | Buy | Chardan Capital Markets |
| 3/6/2025 | $42.00 | Outperform | Wedbush |
| 12/6/2024 | $50.00 | Outperform | BMO Capital Markets |
| 11/11/2024 | $48.00 → $49.00 | Buy | H.C. Wainwright |
| 12/15/2023 | $41.00 | Buy | Jefferies |
| 12/4/2023 | $48.00 | Buy | H.C. Wainwright |
| 11/17/2023 | $43.00 | Buy | Truist |
| 10/31/2023 | $50.00 | Buy | Guggenheim |